Corrigendum: Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression [Ann Oncol, 25, (2014) (1551-1557)] doi: 10.1093/annonc/mdu186

Ulrike Nitz; O. Gluz; J. Huober; H. H. Kreipe; R. E. Kates; A. Hartmann; R. Erber; Z. Moustafa; M. Scholz; B. Lisboa; S. Mohrmann; V. Möbus; D. Augustin; G. Hoffmann; E. Weiss; S. Böhmer; R. Kreienberg; A. Du Bois; D. Sattler; C. Thomssen; M. Kiechle; F. Jänicke; D. Wallwiener; N. Harbeck; W. Kuhn

doi:10.1093/annonc/mdw349

Corrigendum: Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression [Ann Oncol, 25, (2014) (1551-1557)] doi: 10.1093/annonc/mdu186

Ulrike Nitz, O. Gluz, J. Huober, H. H. Kreipe, R. E. Kates, A. Hartmann, R. Erber, Z. Moustafa, M. Scholz, B. Lisboa, S. Mohrmann, V. Möbus, D. Augustin, G. Hoffmann, E. Weiss, S. Böhmer, R. Kreienberg, A. Du Bois, D. Sattler, C. ThomssenM. Kiechle, F. Jänicke, D. Wallwiener, N. Harbeck, W. Kuhn

Chair of Gynaecology

Research output: Contribution to journal › Comment/debate

4 Scopus citations

Original language	English
Pages (from-to)	2899
Number of pages	1
Journal	Annals of Oncology
Volume	28
Issue number	11
DOIs	https://doi.org/10.1093/annonc/mdw349
State	Published - Nov 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdw349

Cite this

Nitz, U., Gluz, O., Huober, J., Kreipe, H. H., Kates, R. E., Hartmann, A., Erber, R., Moustafa, Z., Scholz, M., Lisboa, B., Mohrmann, S., Möbus, V., Augustin, D., Hoffmann, G., Weiss, E., Böhmer, S., Kreienberg, R., Du Bois, A., Sattler, D., ... Kuhn, W. (2017). Corrigendum: Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression [Ann Oncol, 25, (2014) (1551-1557)] doi: 10.1093/annonc/mdu186. Annals of Oncology, 28(11), 2899. https://doi.org/10.1093/annonc/mdw349

@article{99e1da3c3e4341ae80f50e34aea72e9e,

title = "Corrigendum: Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression [Ann Oncol, 25, (2014) (1551-1557)] doi: 10.1093/annonc/mdu186",

author = "Ulrike Nitz and O. Gluz and J. Huober and Kreipe, {H. H.} and Kates, {R. E.} and A. Hartmann and R. Erber and Z. Moustafa and M. Scholz and B. Lisboa and S. Mohrmann and V. M{\"o}bus and D. Augustin and G. Hoffmann and E. Weiss and S. B{\"o}hmer and R. Kreienberg and {Du Bois}, A. and D. Sattler and C. Thomssen and M. Kiechle and F. J{\"a}nicke and D. Wallwiener and N. Harbeck and W. Kuhn",

year = "2017",

month = nov,

doi = "10.1093/annonc/mdw349",

language = "English",

volume = "28",

pages = "2899",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "11",

}

Nitz, U, Gluz, O, Huober, J, Kreipe, HH, Kates, RE, Hartmann, A, Erber, R, Moustafa, Z, Scholz, M, Lisboa, B, Mohrmann, S, Möbus, V, Augustin, D, Hoffmann, G, Weiss, E, Böhmer, S, Kreienberg, R, Du Bois, A, Sattler, D, Thomssen, C, Kiechle, M, Jänicke, F, Wallwiener, D, Harbeck, N & Kuhn, W 2017, 'Corrigendum: Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression [Ann Oncol, 25, (2014) (1551-1557)] doi: 10.1093/annonc/mdu186', Annals of Oncology, vol. 28, no. 11, pp. 2899. https://doi.org/10.1093/annonc/mdw349

Corrigendum: Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression [Ann Oncol, 25, (2014) (1551-1557)] doi: 10.1093/annonc/mdu186. / Nitz, Ulrike; Gluz, O.; Huober, J. et al.
In: Annals of Oncology, Vol. 28, No. 11, 11.2017, p. 2899.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum

T2 - Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression [Ann Oncol, 25, (2014) (1551-1557)] doi: 10.1093/annonc/mdu186

AU - Nitz, Ulrike

AU - Gluz, O.

AU - Huober, J.

AU - Kreipe, H. H.

AU - Kates, R. E.

AU - Hartmann, A.

AU - Erber, R.

AU - Moustafa, Z.

AU - Scholz, M.

AU - Lisboa, B.

AU - Mohrmann, S.

AU - Möbus, V.

AU - Augustin, D.

AU - Hoffmann, G.

AU - Weiss, E.

AU - Böhmer, S.

AU - Kreienberg, R.

AU - Du Bois, A.

AU - Sattler, D.

AU - Thomssen, C.

AU - Kiechle, M.

AU - Jänicke, F.

AU - Wallwiener, D.

AU - Harbeck, N.

AU - Kuhn, W.

PY - 2017/11

Y1 - 2017/11

UR - http://www.scopus.com/inward/record.url?scp=85034079884&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw349

DO - 10.1093/annonc/mdw349

M3 - Comment/debate

C2 - 27634692

AN - SCOPUS:85034079884

SN - 0923-7534

VL - 28

SP - 2899

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A et al. Corrigendum: Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression [Ann Oncol, 25, (2014) (1551-1557)] doi: 10.1093/annonc/mdu186. Annals of Oncology. 2017 Nov;28(11):2899. doi: 10.1093/annonc/mdw349

Corrigendum: Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression [Ann Oncol, 25, (2014) (1551-1557)] doi: 10.1093/annonc/mdu186

UN SDGs

Access to Document

Other files and links

Cite this